Nausea and Vomiting, Postoperative

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Amicus Therapeutics
Amicus TherapeuticsPA - Philadelphia
1 program
1
Amisulpride InjectionPhase 2/31 trial
Active Trials
NCT05546359CompletedEst. Jun 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Amicus TherapeuticsAmisulpride Injection

Clinical Trials (1)

NCT05546359Amicus TherapeuticsAmisulpride Injection

Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

Start: Jan 2024Est. completion: Jun 2025
Phase 2/3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space